These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31782975)

  • 1. Cost-effectiveness of long-acting insulin analogues vs intermediate/long-acting human insulin for type 1 diabetes: A population-based cohort followed over 10 years.
    Lee TY; Kuo S; Yang CY; Ou HT
    Br J Clin Pharmacol; 2020 May; 86(5):852-860. PubMed ID: 31782975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs associated with long-acting insulin analogues in patients with diabetes.
    Alemayehu B; Speiser J; Bloudek L; Sarnes E
    Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP265-SP272. PubMed ID: 30020738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term cost-utility of degludec versus glargine U100 for patients with type 2 diabetes at high risk of hypoglycaemia and cardiovascular events: A Canadian setting (DEVOTE 9).
    Pollock RF; Heller S; Pieber TR; Woo V; Gundgaard J; Hallén N; Luckevich M; Tutkunkardas D; Zinman B;
    Diabetes Obes Metab; 2019 Jul; 21(7):1706-1714. PubMed ID: 30924579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review.
    Yang CY; Chen YR; Ou HT; Kuo S
    Cardiovasc Diabetol; 2021 Jan; 20(1):21. PubMed ID: 33468131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.
    Russel-Szymczyk M; Valov V; Savova A; Manova M
    BMC Endocr Disord; 2019 Dec; 19(1):132. PubMed ID: 31796048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the cost-utility of insulin degludec vs insulin glargine in Sweden.
    Ericsson Å; Pollock RF; Hunt B; Valentine WJ
    J Med Econ; 2013 Dec; 16(12):1442-52. PubMed ID: 24147661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective.
    Evans M; Wolden M; Gundgaard J; Chubb B; Christensen T
    Diabetes Obes Metab; 2014 Apr; 16(4):366-75. PubMed ID: 24373113
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative risks of diabetes-related complications of basal insulins: a longitudinal population-based cohort of type 1 diabetes 1999-2013 in Taiwan.
    Ou HT; Lee TY; Du YF; Li CY
    Br J Clin Pharmacol; 2018 Feb; 84(2):379-391. PubMed ID: 29073329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.
    Pollock RF; Tikkanen CK
    J Med Econ; 2017 Mar; 20(3):213-220. PubMed ID: 27705031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine.
    Misurski D; Lage MJ; Fabunmi R; Boye KS
    Appl Health Econ Health Policy; 2009; 7(4):245-54. PubMed ID: 19905038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources.
    Heller SR; Frier BM; Hersløv ML; Gundgaard J; Gough SC
    Diabet Med; 2016 Apr; 33(4):471-7. PubMed ID: 26179360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial.
    Evans M; Moes RGJ; Pedersen KS; Gundgaard J; Pieber TR
    Adv Ther; 2020 May; 37(5):2413-2426. PubMed ID: 32306247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the cost-effectiveness of reduced mild hypoglycaemia in subjects with Type 1 diabetes treated with insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands.
    Valentine WJ; Jendle J; Saraheimo M; Thorsteinsson B; Pollock RF; Lammert M
    Diabet Med; 2012 Mar; 29(3):303-12. PubMed ID: 21951030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of insulin detemir compared with NPH insulin in people with type 2 diabetes in Denmark, Finland, Norway, and Sweden.
    Ridderstråle M; Jensen MM; Gjesing RP; Niskanen L
    J Med Econ; 2013; 16(4):468-78. PubMed ID: 23384160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Budget Impact of Long-Acting Insulin Analogues: The Case in Brazil.
    Laranjeira FO; Silva EN; Pereira MG
    PLoS One; 2016; 11(12):e0167039. PubMed ID: 27907034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.
    Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B
    Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective.
    Mezquita-Raya P; Darbà J; Ascanio M; Ramírez de Arellano A
    Expert Rev Pharmacoecon Outcomes Res; 2017 Dec; 17(6):587-595. PubMed ID: 28649881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus.
    Horvath K; Jeitler K; Berghold A; Ebrahim SH; Gratzer TW; Plank J; Kaiser T; Pieber TR; Siebenhofer A
    Cochrane Database Syst Rev; 2007 Apr; (2):CD005613. PubMed ID: 17443605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A UK analysis of the cost-effectiveness of Humalog Mix75/25 and Mix50/50 versus long-acting basal insulin.
    Pollock RF; Curtis BH; Smith-Palmer J; Valentine WJ
    Adv Ther; 2012 Dec; 29(12):1051-66. PubMed ID: 23179373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.